becton dickinson compani
usd may pm et
summari compani provid wide rang medic devic diagnost product use
hospit doctor offic research lab set
price-to-earnings oper ep
think warrant medium risk valu rate
compani oper mani competit
market volatil regul shift health care
industri practic also slightli elev
level debt recent year compani
work pay time massiv
scale wide rang product make prefer
vendor health care facil
fiscal year end sep ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
lower target base
forward price-to-earnings multipl fy sep
ep estim mar-q ep vs
exceed consensu estim
higher-than-expect sale
expect bdx busi broadli
howev anticip minor offset
heighten demand covid test medic
suppli infus pump lower fy
ep estim
fy ep estim
segment sale declin yoy life
scienc intervent sale increas
respect medic sale
advers impact alari system
remedi china volume-bas
procur initi expect
disrupt longer
expect file alari
mar-q life scienc sale bolster
strong flu season relat
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
becton dickinson compani
corpor overview becton dickinson compani global medic technolog compani
engag develop manufactur sale broad rang medic suppli devic
laboratori equip diagnost product use healthcar institut life scienc research
clinic laboratori pharmaceut industri gener public one first
compani sell -made glass syring pioneer product hypoderm needl
tradit two busi segment bd medic bd life scienc decemb
acquisit bard bcr compani began report third segment bd
fiscal year end septemb gener billion revenu break-out
billion medic segment billion life scienc billion
intervent fy bdx revenu came outsid ou
fy fy
bd medic segment produc broad array medic technolog devic use help
improv healthcar deliveri wide rang set primari custom serv bd medic
hospit clinic physician offic practic consum retail pharmaci government
nonprofit public health agenc pharmaceut compani healthcar worker organiz
unit segment diabet care medic deliveri solut medic manag solut
pharmaceut system exampl product includ syring pen needl intraven cathet
medic deliveri infus therapi deliveri system pre-fil drug deliveri system
bd life scienc segment provid product safe collect transport diagnost
specimen instrument reagent system detect broad rang infecti diseas
healthcare-associ infect cancer addit bd life scienc produc research clinic
tool facilit studi cell compon cell gain better understand
normal diseas process inform use aid discoveri develop new
drug vaccin improv diagnosi manag diseas primari custom
serv segment hospit laboratori clinic blood bank healthcar worker public
health agenc physician offic practic academ govern institut pharmaceut
biotechnolog compani organiz unit segment includ integr diagnost
solut compris two formerli separ unit preanalyt system diagnost system
bd intervent segment includ major formerli bard product offer
intervent segment broken three organiz unit surgeri peripher intervent
urolog critic care unit includ product hernia soft tissu repair biolog
graft cathet drug coat balloon cancer diagnost
impact major develop decemb close acquisit bard inc bcr
total enterpris valu billion bcr lead develop manufactur market
medic technolog field vascular urolog oncolog surgic specialti acquisit
substanti chang product mix bcr product faster grow clinic area
deal also boost alreadi sizeabl presenc china acquisit
start report new segment bd intervent includ major bcr product
last sizeabl acquisit prior bcr carefus cfn march acquir cfn
lead provid medic devic diagnost product billion acquisit
departur histori bolt-on acquisit integr larg complet may
three year acquisit
financi trend fiscal year end septemb revenu expand
year-over-year currenc neutral basi billion partial aid bcr acquisit
five-year compound annual growth rate compound-annual-growth-rate five-year compound-annual-growth-rate normal ep
fy normal ep increas
septemb net debt total capit ratio leverag ratio net debt
ebitda paid debt relat bcr acquisit quicker expect
expect de-lever end calendar year
execut vice-president research
 develop
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
billion continu face strong currenc headwind howev
expect headwind abat go forward organ basi revenu
grew led growth medic segment follow life
scienc intervent despit unresolv trade tension sale
china grew organ confid tariff environ hurt
busi china look toward fy forecast least earn
growth continu core revenu growth also expect fda
provid posit updat soon usag drug paclitaxel regard
previously-rais concern increas mortal risk associ drug
pm et cfra keep buy opinion share becton dickinson
compani maintain target base
ep estim mar-q ep vs
in-lin consensu expect lower sep ep
maintain ep mar-q sale decreas
billion neg impact strong dollar
worse-than-expect organ basi revenu grew led
growth medic segment follow intervent
life scienc emerg market growth remain strong quarter
bard integr synergi remain track expect compani lower
full-year earn outlook due fda warn march regard
increas mortal risk associ pacliataxel-co devic
drug-coat balloon dcb anticip reduct dcb sale
creat basi point headwind ep growth expect fda updat
june key catalyst /kevin huang cfa
analyst research note compani news
et cfra maintain hold opinion share becton dickinson
compani lower target base forward price-to-earnings
multipl fy sep ep estim mar-q ep
vs exceed consensu estim higher-than-expect
sale expect bdx busi broadli experi
pressur howev anticip minor offset heighten
demand covid test medic suppli infus pump lower fy
ep estim fy ep estim
constant currenc basi mar-q medic segment sale
declin yoy life scienc intervent sale increas
respect medic sale advers impact alari
remedi china volume-bas procur initi
expect disrupt longer expect
file alari mar-q life scienc sale bolster
strong flu season relat test /kevin huang cfa
et cfra lower opinion share becton dickinson compani
hold buy lower target price share
base forward price-to-earnings multipl ep
estim dec-q ep vs consensu
estim share declin pre-market trade unexpect
announc work fda softwar remedi plan
alari pump system process requir submit addit
regulatori file expect complet sep-q reflect
impact alari news lower fy sep ep estim
fy ep previou
quarter earn call alreadi lower guidanc due pend
alari upgrad push sale futur sale alari lead
infus pump appear signific momentum given recent market share
gain today earn call look commentari
long-term impact recent delay /kevin huang cfa
pm et cfra reiter buy opinion share becton dickinson
compani lift target price share
base forward price-to-earnings multipl ep estim
end decemb lift multipl high
end bdx five-year rang think
bdx integr acquir bard busi proceed ahead
expect enabl transform profit firm
expect shift product mix toward higher margin product
continu busi optim effort support low-double-digit ep growth
long-run /kevin huang cfa
pm et cfra maintain buy opinion share becton dickinson
compani lower target price base
multipl ep sep-q ep vs
fell short estim lower fy sep
initi fy ep sep-q sale grew
organ billion slightli expect excit
fiscal year adjust oper margin full year margin
margin expans primarili driven realiz bard
synergi expect drive basi point margin expans
fy revenu growth china fell short expect
constant currenc vs full year metric fell short
expect due price pressur basic medic devic
initi guidanc fy ep
origin expect like continu currenc headwind
chines price pressur fy /kevin huang cfa
pm et cfra reiter buy opinion share becton dickinson
compani keep target below-p
multipl ep estim jun-q ep
vs surpass consensu maintain fy sep ep
lower fy ep jun-q sale grew
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
